Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment
Launched by JOHNS HOPKINS UNIVERSITY · Sep 9, 2016
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
The investigators will study the effect of right cerebellar transcranial direct current stimulation (tDCS) stimulation during language therapy for naming in individuals with chronic aphasia (\>6 months post stroke). Naming difficulties are a persistent and common symptom in aphasia after left-hemisphere (LH) stroke. Although the interventions to improve naming can have benefits, a massive number of treatment sessions is usually required to show gains, particularly in individuals with chronic, large LH stroke. tDCS is a promising adjunct to traditional language therapy. tDCS is a safe, non-i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must have sustained a left hemisphere stroke.
- • Participants must be fluent speakers of English by self-report.
- • Participants must be capable of giving informed consent or indicating another to provide informed consent.
- • Participants must be age 18 or older.
- • Participants must be premorbidly right handed.
- • Participants must be at least 6 months post stroke.
- • Participants must have an aphasia diagnosis as confirmed by the Boston Diagnostic Aphasia Examination (BDAE) Short Form.
- • Participants must achieve at least 65% accuracy on screening task (comparable to treatment task) on 1 of 3 attempts
- Exclusion Criteria:
- • Participants with lesion involving the right cerebellum
- • Previous neurological or psychiatric disease.
- • Seizures during the previous 12 months.
- • Uncorrected visual loss or hearing loss by self-report.
- • Use of medications that lower the seizure threshold (e.g., methylphenidate, amphetamine salts).
- • Use of N-methyl-D-aspartate receptor (NMDA) antagonists (e.g., memantine).
- • \> 80% (140 out of 175) correct responses on the Philadelphia Naming Test at baseline.
- • History of brain surgery or any metal in the head.
- • Scalp sensitivity (per participant report).
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Rajani Sebastian, PhD, CCC-SLP
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials